<h1>100% US tariff on branded patented drugs from Oct 2025 unlikely to hit India's pharma exports largely made of generics</h1> A US presidential proclamation to impose a 100% tariff from October 2025 on branded or patented pharmaceutical products-waived only where a company is 'building' a US manufacturing plant (defined as breaking ground or under construction)-is unlikely to materially affect Indian pharmaceutical exports, according to the head of India's pharmaceutical export promotion council, because the country's shipments to the US are predominantly generics rather than patented branded drugs. India currently exports about USD 11 billion in pharmaceuticals to the US of roughly USD 30 billion in global pharma exports, suggesting limited exposure to the new tariff.